Business ❯ Finance ❯ Mergers and Acquisitions

Pharmaceuticals

Oncology Eli Lilly Obesity Drugs Biotech Companies AstraZeneca Rare Diseases Life Sciences Torrent Pharmaceuticals Sun Pharmaceutical Industries GSK Alkermes and Avadel Pharmaceuticals Drug Development Generic Drugs Sun Pharma Metsera Lundbeck Gilead Sciences Sun Pharmaceutical Industries Limited Biontech-Curevac Acquisition AbbVie Acquisition of Apogee Therapeutics Royalty Agreements Pfizer Biogen Evoke Pharma, Inc. Bidding Wars Sigma Healthcare GSK Acquisition Zymeworks Acquisition Cancer Drug Development Regulatory Approval Merck Biotechnology Walgreens Business Sale Novo Holdings Acquisition Zymeworks Acquisition of Theravance Biopharma Organon & Co. Crinetics Pharmaceuticals Vertex Pharmaceuticals Psychedelic Medicine GSK Acquisition of Rapt Therapeutics Biopharmaceuticals CNS Medicines Nutrition Bristol Myers Squibb Immunology Novo Nordisk Anti-obesity Drugs Market Impact Biosimilars Zymeworks Inc. AbbVie Biogen Acquisition of Apellis Acquisition of Amicus Therapeutics COPD Treatments Pfizer Inc. Ophthalmology Psychedelic Drugs Legal Disputes JB Chemicals Industry Trends Cidara Therapeutics Biogen and Apellis Acquisition AstraZeneca and Bristol Myers Squibb Merger Biotech Arcellx Antitrust Issues Supernus Pharmaceuticals Psychedelic Therapies Company Acquisitions Gene Therapy Weight Loss Drugs Cardiovascular Drugs 23andMe Neurological Disorders Sanofi

Reuters Says There Were No AstraZeneca‑Bristol Myers Merger Talks

The denial calmed market moves, highlighting steep antitrust and patent hurdles for any proposed megadeal.

AstraZeneca in Talks With Bristol Myers on Potential $400 Billion Merger

Eli Lilly Agrees to Buy Psychedelic Biotech AtaiBeckley for $2.8 Billion

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

Zymeworks to Buy Theravance for $929 Million

AbbVie Agrees to Buy Apogee Therapeutics for $10.9 Billion

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Sun Pharma to Buy Organon for $11.75 Billion in All-Cash Deal

Ligand to Buy XOMA Royalty for $739 Million

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws